These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38095690)

  • 1. Correction: Clinical features and associated factors of intraocular inflammation following intravitreal brolucizumab as switching therapy for neovascular age‑related macular degeneration.
    Sotani R; Matsumiya W; Kim KW; Miki A; Yasuda E; Maeda Y; Hara R; Kusuhara S; Nakamura M
    Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):671. PubMed ID: 38095690
    [No Abstract]   [Full Text] [Related]  

  • 2. First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration.
    Abdin AD; Aljundi W; El Jawhari K; Suffo S; Weinstein I; Seitz B
    Front Pharmacol; 2022; 13():860784. PubMed ID: 35721125
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical features and associated factors of intraocular inflammation following intravitreal brolucizumab as switching therapy for neovascular age-related macular degeneration.
    Sotani R; Matsumiya W; Kim KW; Miki A; Yasuda E; Maeda Y; Hara R; Kusuhara S; Nakamura M
    Graefes Arch Clin Exp Ophthalmol; 2023 Aug; 261(8):2359-2366. PubMed ID: 36971800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular adverse events following intravitreal brolucizumab for neovascular age-related macular degeneration at a single tertiary care center.
    Nguyen HV; Li AS; Silva AR; Leng T
    Eur J Ophthalmol; 2022 Sep; 32(5):2747-2751. PubMed ID: 34761684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment.
    Holz FG; Iida T; Maruko I; Sadda SR
    Retina; 2022 Sep; 42(9):1629-1637. PubMed ID: 35994582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
    Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
    Sci Rep; 2022 May; 12(1):8195. PubMed ID: 35581196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration.
    Kitajima Y; Maruyama-Inoue M; Ikeda S; Ito A; Inoue T; Yanagi Y; Kadonosono K
    Jpn J Ophthalmol; 2022 Nov; 66(6):511-517. PubMed ID: 36149566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
    Matsumoto H; Hoshino J; Nakamura K; Akiyama H
    Sci Rep; 2023 Feb; 13(1):3249. PubMed ID: 36828853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
    Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
    Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study.
    Kim DJ; Jin KW; Han JM; Lee SH; Park YS; Lee JY; Lee EK; Lee JS; Kim ST; Shin MH; Lee CS; Jung HH; Jang JY; Kim M; Kim YH; Kim JH; Park KH; Park SJ; Joo K; Ji YS; Sagong M; Woo SJ
    Ophthalmologica; 2023; 246(3-4):192-202. PubMed ID: 36720210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HAWK Extension Study: Safety and Efficacy of Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration.
    Brown DM; Nowik M; Bouillaud E; Dugel APU;
    Curr Eye Res; 2023 Jan; 48(1):44-50. PubMed ID: 36398628
    [No Abstract]   [Full Text] [Related]  

  • 12. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
    Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
    Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map.
    Khanani AM; Zarbin MA; Barakat MR; Albini TA; Kaiser PK; B G; Agashivala N; Yu JS; Wykoff CC; MacCumber MW
    JAMA Ophthalmol; 2022 Jan; 140(1):20-28. PubMed ID: 34817566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry.
    MacCumber MW; Wykoff CC; Karcher H; Adiguzel E; Sinha SB; Vishwakarma S; LaPrise A; Igwe F; Freitas R; Ip MS; Zarbin MA
    Ophthalmology; 2023 Sep; 130(9):937-946. PubMed ID: 37086857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. INTRAOCULAR INFLAMMATION INCIDENCE AFTER INTRAVITREAL BROLUCIZUMAB INJECTION FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Pakravan P; Patel V; Lai J; Shaheen A; Kalahasty K; Reyes-Capo DP; Chau V; Rosenfeld PJ; Haddock LJ; Schwartz SG; Smiddy WE; Kovach JL; Sridhar J; Flynn HW; Albini TA; Yannuzzi NA
    Retina; 2023 Oct; 43(10):1717-1722. PubMed ID: 37320859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation.
    Shigemoto Y; Sakurada Y; Fukuda Y; Matsubara M; Parikh R; Kashiwagi K
    Medicine (Baltimore); 2021 Oct; 100(42):e27580. PubMed ID: 34678906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and Management of Intraocular Inflammation after Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration.
    Bodaghi B; Souied EH; Tadayoni R; Weber M; Ponthieux A; Kodjikian L
    Ophthalmol Retina; 2023 Oct; 7(10):879-891. PubMed ID: 37343623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to Brolucizumab.
    MacCumber MW; Wykoff CC; Karcher H; Adiguzel E; Sinha SB; Vishwakarma S; LaPrise A; Igwe F; Freitas R; Ip MS; Zarbin MA
    Ophthalmology; 2023 Aug; 130(8):795-803. PubMed ID: 36990322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
    Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
    Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.
    Enríquez AB; Baumal CR; Crane AM; Witkin AJ; Lally DR; Liang MC; Enríquez JR; Eichenbaum DA
    JAMA Ophthalmol; 2021 Apr; 139(4):441-448. PubMed ID: 33630045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.